Drug resistance-related mutations in multidrug-resistant Mycobacterium tuberculosis isolates from diverse geographical regions

International Journal of Mycobacteriology

Volumn 1, Issue 3, 2012, Pages 124-130

  Rosales Klintz, Senia ^a,b,c   Jureen, Pontus ^b,c   Zalutskayae, Aksana ^d   Skrahina, Alena ^d   Xu, Biao ^e   Hu, Yi ^e   Pineda Garcia, Lelany ^a   Merza, Muayad Aghali ^f,g   Muntean, Ionela ^h   Bwanga, Freddie ⁱ   Joloba, Moses ⁱ   Hoffner, Sven E ^b,c  

^a NATIONAL AUTONOMOUS UNIVERSITY OF HONDURAS   (Honduras)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^d Center for Epidemiology and Microbiology   (Belarus)

^e FUDAN UNIVERSITY   (China)

^f UNIVERSITY OF DUHOK   (Iraq)

^g SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^h Pneumophtisiology Hospital   (Romania)

ⁱ MAKERERE UNIVERSITY   (Uganda)

Author keywords

GyrA gene; KatG gene; MabA inhA operon; MDR TB; RpoB gene

Indexed keywords

ISONIAZID; KATG PROTEIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATION; BELARUS; BIOGEOGRAPHIC REGION; CHINA; GENE FREQUENCY; GENE MUTATION; GYRA GENE; HONDURAS; INCIDENCE; IRAN; IRAQ; KATG GENE; MABA INHA GENE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; ORGANISMS BY GEOGRAPHICAL DISTRIBUTION; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; ROMANIA; RPOB GENE; UGANDA;

MYCOBACTERIUM TUBERCULOSIS;

EID: 84884388975     PISSN: 22125531     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijmyco.2012.08.001     Document Type: Article

References (33)

1. World Health Organization, Global tuberculosis control: WHO Report 2011, WHO/HTM/2011.16, World Health Organization, Geneva, Switzerland, 2011.
2. World Health Organization, Report of the meeting of the WHO Global Task force on XDR-TB, WHO/HTM/TB/2007.275, World Health Organization, Geneva, Switzerland, 2007.
3. Skrahina A., Hurevics H., Zalutskaya A., Sahalchyk E., Astrauko A., van Gemert W., et al. Alarming levels of drug-resistant tuberculosis in Belarus: Results of a survey in Minsk. Eur. Respir. J. 2012, 39(6):1425-1431.
4. Ramaswamy S., Musser J.M. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuberc. Lung Dis. 1998, 79(1998):3-29.
5. Telenti A., Imboden P., Marchesi F., Lowrie D., Cole S., Colston M.J., et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993, 341:647-650.
6. Heym B., Saint-Joanis B., Cole S.T. The molecular basis of isoniazid resistance in Mycobacterium tuberculosis. Tuberc. Lung Dis. 1999, 79:267-271.
7. Rouse D.A., Li Z., Bai G.H., Morris S.L. Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 1995, 39:2472-2477.
8. Banerjee A., Sugantino M., Sacchettini J.C., Jacobs W.R. The mabA gene from the inhA operon of Mycobacterium tuberculosis encodes a 3-ketoacyl reductase that fails to confer isoniazid resistance. Microbiology 1998, 144(Pt 10):2697-2704.
9. Canetti G., Fox W., Khomenko A., Mahler H.T., Menon N.K., Mitchison D.A., et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull. World Health Organ. 1969, 41:21-43.
10. Canetti G., Froman S., Grosset J., Hauduroy P. Mycobacteria: Laboratory methods for testing drug sensitivity and resistance. Bull. World Health Organ. 1963, 29:565-568.
11. Reisner B.S., Gatson A.M., Woods G.L. Evaluation of mycobacteria growth indicator tubes for susceptibility testing of Mycobacterium tuberculosis to isoniazid and rifampin. Diagn. Microbiol. Infect. Dis. 1995, 22:325-329.
12. Jureen P., Werngren J., Hoffner S.E. Evaluation of the line probe assay (LiPA) for rapid detection of rifampicin resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb.) 2004, 84:311-316.
13. van Soolingen D., Hermans P.W., de Haas P.E., Soll D.R., van Embden J.D. Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: Evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J. Clin. Microbiol. 1991, 29:2578-2586.
14. Sun Z., Zhang J., Zhang X., Wang S., Zhang Y., Li C. Comparison of gyrA gene mutation between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. Int. J. Antimicrob. Agents 2008, 31:115-121.
15. Xu C., Kreiswirth N., Sreevatsan S., Musser J.M., Drlica K. Fluoroquinolone resistance associated with specific gyrase mutation in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J. Infect. Dis. 1996, 174:1127-1130.
16. Thompson J.D., Higgins D.G., Gibson T.J. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22:4673-4680.
17. Sandgren A., Strong M., Muthukrishnan P., Weiner B.K., Church G.M., Murray M.B. Tuberculosis drug resistance mutation database. PLoS Med. 2009, 6:e2.
18. Sreevatsan S., Pan X., Stockbauer K.E., Connell N.D., Kreiswirth B.N., Whittam T.S., et al. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc. Natl. Acad. Sci. USA 1997, 94:9869-9874.
19. Hazbon M.H., Brimacombe M., Bobadilla del Valle M., Cavatore M., Guerrero M.I., Varma-Basil M., et al. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2006, 50:2640-2649.
20. Chan R.C., Hui M., Chan E.W., Au T.K., Chin M.L., Yip C.K., et al. Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong. J. Antimicrob. Chemother. 2007, 59:866-873.
21. Kapur V., Li L.L., Iordanescu S., Hamrick M.R., Wanger A., Kreiswirth B.N., et al. Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J. Clin. Microbiol. 1994, 32:1095-1098.
22. Dalla Costa E.R., Ribeiro M.O., Silva M.S., Arnold L.S., Rostirolla D.C., Cafrune P.I., et al. Correlations of mutations in katG, oxyR-ahpC and inhA genes and in vitro susceptibility in Mycobacterium tuberculosis clinical strains segregated by spoligotype families from tuberculosis prevalent countries in South America. BMC Microbiol. 2009, 9:39.
23. Von Groll A., Martin A., Jureen P., Hoffner S., Vandamme P., Portaels F., et al. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob. Agents Chemother. 2009, 53:4498-4500.
24. Setareh M., Titov L.P., Surkova L.K. High level association of mutation in KatG315 with MDR and XDR clinical isolates of Mycobacterium tuberculosis in Belarus. Acta Microbiol. Immunol. Hung. 2009, 56:313-325.
25. Bazira J., Asiimwe B.B., Joloba M.L., Bwanga F., Matee M.I. Use of the GenoType® MTBDRplus assay to assess drug resistance of Mycobacterium tuberculosis isolates from patients in rural Uganda. BMC Clin. Pathol. 2010, 10:5.
26. Umubyeyi A.N., Rigouts L., Shamputa I.C., Fissette K., Elkrim Y., de Rijk P.W., et al. Limited fluoroquinolone resistance among Mycobacterium tuberculosis isolates from Rwanda: Results of a national survey. J. Antimicrob. Chemother. 2007, 59:1031-1033.
27. Aubry A., Veziris N., Cambau E., Truffot-Pernot C., Jarlier V., Fisher L.M. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: Functional analysis of mutant enzymes. Antimicrob. Agents Chemother. 2006, 50:104-112.
28. Maruri F., Sterling T.R., Kaiga A.N., Blackman A., van der Hejden Y.F., Mayer C., et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed numbering system. J. Antimicrob. Chemother. 2012, 67:819-831.
29. Hu Y., Ma X., Graviss E.A., Wang W., Jiang W., Xu B. A major subgroup of Beijing family Mycobacterium tuberculosis is associated with multidrug resistance and increased transmissibility. Epidemiol. Infect. 2010, 1-9.
30. Doustdar F., Khosravi A.D., Farnia P., Masjedi M.R., Velayati A.A. Molecular analysis of isoniazid resistance in different genotypes of Mycobacterium tuberculosis isolates from Iran. Microb. Drug Resist. 2008, 14:273-279.
31. Hillemann D., Rusch-Gerdes S., Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J. Clin. Microbiol. 2007, 45:2635-2640.
32. Hillemann D., Rusch-Gerdes S., Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis Strains and Clinical Specimens. J. Clin. Microbiol. 2009, 47:1767-1772.
33. Ignatyeva O., Konstsevaya I., Kovalyov A., Balbanova Y., Nikolayevskyy V., Toit K., et al. Detection of resistance to second-line antituberculosis drugs by use of GenoType MTBDRsl assay: A multicenter evaluation and feasibility study. J. Clin. Microbiol. 2012, 50:1593-1797.